Improving Survival Rates Among Heart Failure Patients with the Use of Novel Drugs


Dr PK Hazra, Kolkata    04 January 2018

Approximately 40,000-50,000 CA/HF patients receive international device therapies like pacemakers, ICD, CRT and/or RFA.2 In Asia Pacific region, patients receive lower-than-recommended levels of pharmacological treatment.3 The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomous systems.4 In 2016, the focused pharmacologic update on the current Heart Failure Guidelines introduced the use of two newly approved drug regimens: Valsartan/sacubitril and ivabradine. These novel compounds were reported to exert additional mortality and morbidity benefits in heart failure subpopulations with reduced ejection fraction.4


  1. Dokainish H, et al. Lancet Glob Health. 2017;5(7):e665-e672. 2Vora A, et al. Indian Heart J. 2017;69(2):229-39. 3Rajadurai J, et al. J Card Fail. 2017;23(4):327-39. 4Papadimitriou L, et al. Trends Cardiovasc Med. 2017;27(5):316-23.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.